Cardiovascular Disease Doctors in Manchester, CT Accepting Medicare

6 Cardiovascular Disease doctors found. Showing 1 - 6

Prof. Hazar Dahhan, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 Main St, Manchester, CT 06042 Phone: 860-643-5443    Fax: 860-643-9399

Dr. Sun King Wan, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 257 E Center St, Manchester, CT 06040 Phone: 860-643-5101    Fax: 860-533-9747

Dr. Joseph Hanna, M.D. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 18 Haynes St, Manchester, CT 06040 Phone: 860-649-7557

Mr. Parveen Khanna, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 43 W Middle Tpke, Manchester, CT 06040 Phone: 860-647-9494    Fax: 860-646-4892

Dr. Saqib Naseer, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 257 E Center St, Manchester, CT 06040 Phone: 860-643-5101    Fax: 860-533-9747

Mr. Venkateswara Narla, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 43 W Middle Tpke, Manchester, CT 06040 Phone: 860-647-9494    Fax: 860-646-4892

News Archive

MetaVision SafeTrack chosen by University Hospital Southampton for electronic observations

iMDsoft announced that University Hospital Southampton NHS Foundation Trust (UHS) in the UK chose MetaVision SafeTrack™, iMDsoft's new mobile electronic observation solution, for all 1237 of its general ward level 1 beds. This agreement follows the hospital's choice of the MetaVision® Patient Data Management System (PDMS) for all of their high acuity environments.

Diet low in fermented carbs improves quality of life for patients with IBD

A new study has found that the FODMAP diet can improve gut symptoms and quality of life among patients with inflammatory bowel disease (IBD) in just one month.

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

The National Institute for Health and Care Excellence today issued its Final Appraisal Determination (FAD) recommending Xofigo (radium-223 dichloride) for use on the NHS in England as an option for treating adult men, with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

Read more Medical News

› Verified 9 days ago